CAR-T Meeting 2022 | Autologous and allogeneic CAR-Ts & the role of academia within this field
Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, Netherlands, summarizes the key points from a discussion on allogeneic vs autologous chimeric antigen receptor T-cells (CAR-Ts) that took place at this year’s EBMT-EHA CAR T-cell Meeting. Whilst today, it is not feasible to produce and use allogeneic CAR-Ts in a clinical setting, it is expected that they will have a significant role in the future of CAR-T therapy. The role of academia within that field, however, remains unclear. According to Prof. Kuball, academia should play a role in both creating innovations in CAR-T therapy and supporting niche indications. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
JK is co-founder and shareholder of Gadeta and holds patents on different types of engineered immune cells and immune cell selection licensed to different commercial partners and receives revenues. JK received research support from Gadeta, Novartis, Miltenyi Biotech. For more details please visit https://www.umcutrecht.nl/en/research/researchers/kuball-jhe .
